Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPECC1-DT (SPECC1 divergent transcript) is a long non-coding RNA (lncRNA) gene. It is transcribed in a direction divergent to the protein-coding gene SPECC1 (sperm antigen with calponin homology and coiled-coil domains 1). SPECC1-DT does not encode a protein and has not been established as a therapeutic target, receptor, enzyme, transporter, or other functional target class in drug discovery[3]. There is currently no evidence for its involvement in classical molecular pathways or for its direct association with disease processes as a biomarker or therapeutic intervention point. Most research and functional associations relate to the protein-coding gene SPECC1 rather than SPECC1-DT[1][2][4]. Additional Notes: - is_incorrect: true. The name refers to a non-coding RNA, not a validated therapeutic target such as a receptor or enzyme. - There is potential for confusion with the related coding gene "SPECC1" and its circular RNA forms (circSPECC1), which do have roles in cancer biology; however, SPECC1-DT itself remains poorly characterized and is not currently considered a drug target[3].
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPECC1 divergent transcript (SPECC1-DT).